. .
Ide-cel is a CAR-T therapy that involves removing immune cells from a patient, inventing them to attack tumor cells and return them to the patient.
Last year Bristol Myers Squibb and his bluebird bio partner submitted his bid for ide-cel after the US drug regulator refused to review the treatment and seek more information.
As part of the Celgene-Bristol Myers contract, Celgene shareholders would have been paid $ 9 per share if three of Celgene’s major piping funds had been agreed with specific dates.
However, the FDA did not approve a blood cancer treatment, liso-cel, until the end of 2020 and as a result the CVR approval was terminated. (bit.ly/3lS3Gn8)
Reporting by Mrinalika Roy and Anirudh Saligrama in Bengaluru; Edited by Simon Cameron-Moore